Our mission is clear: To build a breakthrough oncology company creating neoantigen-based therapeutics that significantly improve the lives of patients.

Neon Therapeutics leads the neoantigen field in cancer immunotherapy by focusing on key scientific capabilities, including mass spectrometry, bioinformatics, T cell biology, peptide chemistry, personal manufacturing and immune monitoring. These key scientific capabilities support multiple clinical strategies that target neoantigens to deliver a potent attack on tumors, with the aim of creating and deepening anti-tumor immune responses, and broadening the range of cancers treatable via immuno-oncology approaches.

Headquartered in Cambridge, Massachusetts, Neon Therapeutics is a private company launched in 2015. Neon Therapeutics has raised $125 million in private financing to date from Third Rock Ventures, Clal Biotechnology Industries, Access Industries, Partner Fund Management, Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures, Nextech Invest and others.


Scientific Founders

James Allison, Ph.D.
MD Anderson Cancer Center
Ed Fritsch, Ph.D.
Neon Therapeutics
Nir Hacohen, Ph.D.
Broad Institute
Eric Lander, Ph.D.
Broad Institute
Robert Schreiber, Ph.D.
Washington University
Ton Schumacher, Ph.D.
Netherlands Cancer Institute
Catherine Wu, M.D.
Dana-Farber Cancer Institute

Board of Directors

Cary Pfeffer, M.D.
Chairman; Partner, Third Rock Ventures
Robert Kamen, Ph.D.
Entrepreneur-In-Residence, Third Rock Ventures
Eric Lander, Ph.D.
Founding Director, Broad Institute
Hugh O’Dowd, M.B.A.
Chief Executive Officer, Neon Therapeutics
Stephen Sherwin, M.D.
Clinical Professor of Medicine, University of California San Francisco
Robert Tepper, M.D.
Partner, Third Rock Ventures

Scientific Advisors

Nina Bhardwaj, M.D., Ph.D.
Director of Immunotherapy, Professor of Medicine, Division of Hematology & Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Keith T. Flaherty, M.D.
Professor of Medicine, Harvard Medical School; Director, the Henri and Belinda Termeer Center for Targeted Therapy, Director of Clinical Research, Massachusetts General Hospital
John B. Haanen, M.D., Ph.D.
Head of Medical Oncology, Staff Scientist, Netherlands Cancer Institute; Professor, Leiden University Medical Centre
Roy S. Herbst, M.D., Ph.D.
Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Yale School of Medicine
Padmanee Sharma, M.D., Ph.D.
Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
Jedd Wolchok, M.D., Ph.D.
Chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center